Odinwell reported lower Q1 revenue and a stable net loss, with strong equity and cash positions. The company advanced its clinical pipeline, secured new funding, and expanded its patent portfolio, positioning for future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.